SARS-CoV-2 reinfection in patients negative for immunoglobulin G following recovery from COVID-19

被引:27
作者
Ali, A. M. [1 ,2 ]
Ali, K. M. [3 ]
Fatah, M. H. [3 ]
Tawfeeq, H. M. [3 ]
Rostam, H. M. [4 ,5 ]
机构
[1] Univ Garmian, Dept Chem, Coll Sci, Kalar, Kurdistan Regio, Iraq
[2] Sulaimani Polytechn Univ, COVID 19 Lab, Qala Hosp, Garmian Gen Directorate Hlth,Minist Hlth, Kalar, Kurdistan Regio, Iraq
[3] Sulaimani Polytechn Univ, Med Lab Technol Dept, Kalar, Kurdistan Regio, Iraq
[4] Univ Nottingham, Immunol & Immunobioengn Grp, Sch Life Sci, Fac Med & Hlth Sci, Nottingham NG7 2RD, England
[5] Univ Garmian, Coll Med, Kalar, Kurdistan Regio, Iraq
关键词
COVID-19; immunoglobulin G; reinfection; SARS-CoV-2;
D O I
10.1016/j.nmni.2021.100926
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
While many patients infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) eventually produce neutralising antibodies, the degree of susceptibility of previously infected individuals to reinfection by SARS-CoV-2 is currently unknown. To better understand the impact of the immunoglobulin (IgG) level on reinfection in recovered coronavirus disease 2019 (COVID-19) patients, anti-nucleocapsid IgG levels against SARS-CoV-2 were measured in 829 patients with a previously confirmed infection just after their recovery. Notably, 87 of these patients had no detectable IgG concentration. While there was just one case of asymptomatic reinfection 4.5 months after the initial recovery amongst patients with detectable anti-nucleocapsid IgG levels, 25 of the 87 patients negative for anti-nucleocapsid IgG were reinfected within one to three months after their first infection. Therefore, patients who recover from COVID-19 with no detectable anti-nucleocapsid IgG concentration appear to remain more susceptible to reinfection by SARS-CoV-2, with no apparent immunity. Also, although our results suggest the chance is lower, the possibility for recovered patients with positive anti-nucleocapsid IgG findings to be reinfected similarly exists. (c) 2021 The Author(s). Published by Elsevier Ltd.
引用
收藏
页数:7
相关论文
共 43 条
[1]  
Ali KM, 2020, HYPOALBUMINEMIA SEVE
[2]  
Bendavid E, MEDRXIV2020041420062
[3]   Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals [J].
Brochot, Etienne ;
Demey, Baptiste ;
Touze, Antoine ;
Belouzard, Sandrine ;
Dubuisson, Jean ;
Schmit, Jean-Luc ;
Duverlie, Gilles ;
Francois, Catherine ;
Castelain, Sandrine ;
Helle, Francois .
FRONTIERS IN MICROBIOLOGY, 2020, 11
[4]  
Burbelo PD, 2020, MEDRXIV2020042020071
[5]   A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster [J].
Chan, Jasper Fuk-Woo ;
Yuan, Shuofeng ;
Kok, Kin-Hang ;
To, Kelvin Kai-Wang ;
Chu, Hin ;
Yang, Jin ;
Xing, Fanfan ;
Liu, Jieling ;
Yip, Cyril Chik-Yan ;
Poon, Rosana Wing-Shan ;
Tsoi, Hoi-Wah ;
Lo, Simon Kam-Fai ;
Chan, Kwok-Hung ;
Poon, Vincent Kwok-Man ;
Chan, Wan-Mui ;
Ip, Jonathan Daniel ;
Cai, Jian-Piao ;
Cheng, Vincent Chi-Chung ;
Chen, Honglin ;
Hui, Christopher Kim-Ming ;
Yuen, Kwok-Yung .
LANCET, 2020, 395 (10223) :514-523
[6]   Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report [J].
Chen, Dabiao ;
Xu, Wenxiong ;
Lei, Ziying ;
Huang, Zhanlian ;
Liu, Jing ;
Gao, Zhiliang ;
Peng, Liang .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 93 :297-299
[7]   Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J].
Chen, Nanshan ;
Zhou, Min ;
Dong, Xuan ;
Qu, Jieming ;
Gong, Fengyun ;
Han, Yang ;
Qiu, Yang ;
Wang, Jingli ;
Liu, Ying ;
Wei, Yuan ;
Xia, Jia'an ;
Yu, Ting ;
Zhang, Xinxin ;
Zhang, Li .
LANCET, 2020, 395 (10223) :507-513
[8]   Host susceptibility to severe influenza A virus infection [J].
Clohisey, Sara ;
Baillie, John Kenneth .
CRITICAL CARE, 2019, 23 (01)
[9]   Covid-19: four fifths of cases are asymptomatic, China figures indicate [J].
Day, Michael .
BMJ-BRITISH MEDICAL JOURNAL, 2020, 369 :m1375
[10]   COVID-19: Immunology and treatment options [J].
Felsenstein, Susanna ;
Herbert, Jenny A. ;
McNamara, Paul S. ;
Hedrich, Christian M. .
CLINICAL IMMUNOLOGY, 2020, 215